HOUSTON (MedPage Today) -- A majority of patients with type 2 neurofibromatosis had objective tumor responses to treatment with bevacizumab (Avastin), data from a small clinical trial showed.
VEGF Inhibitor Shows Promise in Neurofibromatosis (CME/CE)Courtesy MedPage Today Surgery Wed, 07/08/2009 - 15:00
HOUSTON (MedPage Today) -- A majority of patients with type 2 neurofibromatosis had objective tumor responses to treatment with bevacizumab (Avastin), data from a small clinical trial showed. More related itemsSABCS: Delay Chemo to Aid Wound Healing (CME/CE)
Avastin Stems Vision Loss in Diabetics, Cataract...
SIR: Early Wound Healing Problematic With Bevacizumab
|
Post new comment